List of Progress in Hematology "Review Series" 2012-2013
***2013***
Recent advances in genetic basis of childhood hemato-oncological diseases (Edited by Shuki Mizutani)
1. Urayama KY, Chokkalingam AP, Manabe A, Mizutani S. Current evidence for an inherited genetic basis of childhood acute
lymphoblastic leukemia. Int. J. Hematol. 97:3-19, 2013
2. Sakaguchi H, Nakanishi K, Kojima S. Inherited bone marrow failure syndromes in 2012. Int. J. Hematol. 97:20-29, 2013
3. Aoki Y, Matsubara Y. Ras/MAPK syndromes and childhood hemato-oncological diseases. Int. J. Hematol. 97:30-36, 2013
4. Mizutani S, Takagi M. XCIND as a genetic disease of X-irradiation hypersensitivity and cancer Susceptibility. Int. J. Hematol.
97:37-42, 2013
Genetic and epigenetic alterations in hematopoietic malignancies (Edited by Toshio Kitamura)
1.
Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int. J. Hematol. 97:165-174, 2013
2.
Yamazaki J, Issa J-P.J. Epigenetic aspects of MDS and its molecular targeted therapy. Int. J. Hematol. 97:175-182, 2013
3.
Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders Int. J. Hematol. 97:183-197, 2013
4.
Vu LP., Luciani L, Nimer SD. Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic
potential Int. J. Hematol. 97:198-209, 2013
Basic and Clinical Updates in Multiple Myeloma (Edited by Masahiro Kizaki)
1. Hosen N, Multiple myeloma-initiating cells. Int. J. Hematol. 97:306-312, 2013
2. Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int. J. Hematol. 97:313-323, 2013
3. Hideshima T, Anderson KC. Histone deacetylase inhibitors in the treatment for multiple myeloma Int. J. Hematol. 97:324-322, 2013
4. Watanabe R, Tokuhira M, Kizaki M. Current approaches for the treatment of multiple myeloma. Int. J. Hematol. 97:333-344, 2013
Advances in the Management of Acquired Aplastic Anemia (AA) (Edited by Shinji Nakao)
1. Scheinberg P, Prognostic value of telomere attrition in patients with aplastic anemia. Int. J. Hematol. 97: 553-557, 2013
2. Yamazaki H, Nakao S, Border between aplastic anemia and myelodysplastic syndrome. Int. J. Hematol. 97: 558-563, 2013
3. Shin SH, Lee JW, The optimal immunosuppressive therapy for aplastic anemia. Int. J. Hematol. 97: 564-572, 2013
4. Gandhi S, Kulasekararaj AG, Mufti GJ, Marsh JC. Allogeneic stem cell transplantation using alemtuzumab-containing regimens
in severe aplastic anemia. Int. J. Hematol. 97: 573-580, 2013
Efficacy and resistance of molecularly targeted therapy for myeloid malignancies (Edited by Hitoshi Kiyoi)
1. Grunwald MR, Levis MJ, FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int. J.
Hematol. 97: 683-694, 2013
2. Bhagwat N, Levine RL, Koppikar P, Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. Int. J.
Hematol.97: 695-702, 2013
3. Takeshita A, Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia. Int. J. Hematol. 97: 703-716, 2013
4. Tomita A, Kiyoi H, Naoe T, Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in
acute promyelocytic leukemia. Int. J. Hematol. 97: 717-725, 2013
Pathophysiology and management of thrombocytopenia: Possible clinical application of TPO receptor agonists (Edited by Yoshiaki
Tomiyama)
1. Kuter DJ, The biology of thrombopoietin and thrombopoietin receptor agonists. Int. J. Hematol. 98: 10-23, 2013
2. Kashiwagi H, Tomiyama Y, Pathophysiology and management of primary immune thrombocytopenia, Int. J. Hematol. 98:24-33,
2013
3. Pecci A, Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists,
Int. J. Hematol. 98: 34-47, 2013
4. Townsley DM, Desmond R, Dunbar CE, Young NS, Pathophysiology and management of thrombocytopenia in bone marrow failure:
possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes, Int. J. Hematol. 98: 48-55,
2013
New clinical and basic aspects of graft-versus-host disease (Edited by Akiyoshi Takami)
1. Paczesny S, Raiker N, Brooks S, Mumaw C, Graft-versus-host disease biomarkers: omics and personalized medicine, Int. J. Hematol.
98: 275-292, 2013
2. Maeda Y., Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses, Int. J. Hematol. 98:
293-299, 2013
3. Kanda J, Effect of HLA mismatch on acute graft-versus-host disease, Int. J. Hematol. 98: 300-308, 2013
4. Takami A, The role of non-HLA gene polymorphisms in graft-versus-host disease, Int. J. Hematol. 98: 309-318, 2013
Leukemia Stem Cell (Edited by Koichi Akashi)
1. Kikushige Y., Miyamoto T., TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells, Int. J.
Hematol. 98: 627-633, 2013
2. Ishikawa F., Modeling normal and malignant human hematopoiesis in vivo through newborn NSG xenotransplantation, Int. J.
Hematol. 98: 634-640, 2013
3. Ito T., Stem cell maintenance and disease progression in chronic myeloid leukemia, Int. J. Hematol. 98: 641-647, 2013
4. Chan S.M., Majeti R., Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem
cells in acute myeloid leukemia, Int. J. Hematol. 98: 648-657, 201398: 275-292, 2013
***2012***
Dysplastic myelopoiesis—from the second JSH International Symposium (Edited by Yasushi Miyazaki)
1. Nikoloski G, van der Reijden BA, Jansen JH. Mutations in epigenetic regulators in myelodysplastic syndromes.
Int.
J.
Hematol. 95:8-16, 2012
2. Raaijmakers MH. Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis. Int.
J. Hematol. 95:17-25, 2012
3. Ornstein MC, Sekeres MA.. Combination strategies in myelodysplastic syndromes. Int. J. Hematol. 95:26-33, 2012
Vascular biology with relation to hematopoiesis (Edited by Nobuyuki Takakura)
1. Matsui H. Endothelial progenitor cell-based therapy for hemophilia A. Int. J. Hematol. 95:119-124, 2012
2. Mizukami Y, Sasajima J, Ashida T, Kohgo Y. Abnormal tumor vasculatures and bone marrow-derived pro-angiogenic cells in cancer.
Int. J. Hematol. 95:125-130, 2012
3. Heissig B, Ohki-Koizumi M, Tashiro Y, Gritli I, Sato-Kusubata K, Hattori K. New functions of the fibrinolytic system in bone
marrow cell-derived angiogenesis. Int. J. Hematol. 95:131-137, 2012
4. Takakura N. Involvement of non-vascular stem cells in blood vessel formation. Int. J. Hematol. 95:138-142, 2012
Radiation injury to human body—acute and late hematopoietic organ damage (Edited by Masao Tomonaga)
1. Asano S. Current status of hematopoietic stem cell transplantation for acute radiation syndromes. Int. J. Hematol. 95: 227-231, 2012
2. Tsushima H, Iwanaga M, Miyazaki Y. Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic
syndromes. Int. J. Hematol. 95:232-238, 2012
3. Masuda Y, Kamiya K. Molecular nature of radiation injury and DNA repair disorders associated with radiosensitivity. Int. J.
Hematol. 95:239-245, 2012
Current understanding of thrombosis and hemostasis—from bench to bedside (Edited by Toshiyuki Miyata)
1. Griffin JH, Zlokovic BV, Mosnier LO. Protein C anticoagulant and cytoprotective pathways. Int. J. Hematol. 95:333-345, 2012
2. Morrissey JH. Polyphosphate: a link between platelets, coagulation and inflammation. Int. J. Hematol. 95:346-352, 2012
3. Denis CV, Lenting PJ. von Willebrand factor: at the crossroads of bleeding and thrombosis. Int. J. Hematol. 95:353-361, 2012
4. Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection
control. Int. J. Hematol. 95:362-370, 2012
Hypoxia and Biology (Edited by Nobuhito Goda)
1. Goda N, Kanai M. Hypoxia-inducible factors and their roles in energy metabolism. Int. J. Hematol. 95:457-463, 2012
2. Mucaj V, Shay JE, Simon MC. Effects of hypoxia and HIFs on cancer metabolism. Int. J. Hematol. 95:464-470, 2012
3. Evans CE, Branco-Price C, Johnson RS. HIF-mediated endothelial response during cancer progression. Int. J. Hematol. 95:471-477,
2012
4. Takubo K, Suda T. Roles of the hypoxia response system in hematopoietic and leukemic stem cells. Int. J. Hematol. 95:478-483, 2012
Disease modeling and treatment by iPS cells (Edited by Koji Eto)
1. Ye Z, Chou BK, Cheng L. Promise and challenges of human iPSC-based hematologic disease modeling and treatment. Int. J.
Hematol. 95:601-609, 2012
2. Ebihara Y, Ma F, Tsuji K. Generation of red blood cells from human embryonic/induced pluripotent stem cells for blood transfusion.
Int. J. Hematol. 95:610-616, 2012
3. Togarrati PP, Suknuntha K. Generation of mature hematopoietic cells from human pluripotent stem cells. Int. J. Hematol.
95:617-623, 2012
4. Watarai H, Yamada D, Fujii S, Taniguchi M, Koseki H. Induced pluripotency as a potential path towards iNKT cell-mediated cancer
immunotherapy.. Int. J. Hematol. 95:624-631, 2012
How to improve the outcome of adult acute myeloid leukemia? (Edited by Tomoki Naoe)
1. Kühnl A, Grimwade D. Molecular markers in acute myeloid leukaemia. Int. J. Hematol. 96:153-163, 2012
2. Stein EM, Tallman MS. Remission induction in acute myeloid leukemia. Int. J. Hematol. 96:164-170, 2012
3. Miyawaki S. Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. Int. J. Hematol. 96:171-177,
2012
4. Ungewickell A, Medeiros BC. Novel agents in acute myeloid leukemia. Int. J. Hematol. 96:178-185, 2012
5. Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int. J. Hematol.
96:186-193, 2012
Epigenetics of Hematopoiesis and Hematopoietic Malignancies (Edited by Atsushi Iwama)
1. Sashida G, Iwama A. Epigenetic regulation of hematopoiesis. Int. J. Hematol. 96:405-412, 2012
2. Chung YR, Schatoff E, Abdel-Wahab O. Epigenetic alterations in hematopoietic malignancies. Int. J. Hematol. 96:413-427, 2012
3. Zhang Y, Chen A, Yan XM, Huang G. Disordered epigenetic regulation in MLL-related leukemia. Int. J. Hematol. 96:428-437, 2012
4. Ogawa S. Splicing factor mutations in myelodysplasia. Int. J. Hematol. 96:438-442, 2012
Current and Future Management of Major Subtypes of Malignant Lymphoma Based on Clinical Trials (Edited by Kensei Tobinai)
1. Eichenauer DA, Engert A. Advances in the treatment of Hodgkin lymphoma. Int. J. Hematol. 96:535-543, 2012
2. Salles G, Ghesquières H. Current and future management of follicular lymphoma. Int. J. Hematol. 96:544-551, 2012
3. Roschewski M, Dunleavy K, Wilson WH. Diffuse large B cell lymphoma: molecular targeted therapy. Int. J. Hematol. 96:552-561,
2012
4. Yamaguchi M. Current and future management of NK/T-cell lymphoma based on clinical trials. Int. J. Hematol.96:562-571, 2012